Sanofi India · NSE: SANOFI · BSE: 500674
Q2 FY25 results · Jul–Sep 2024
Sanofi India reported revenue from operations of ₹524.00 crore (down 26.7% from Q2 FY24) and net profit of ₹82.19 crore (down 45.9% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 524.00 | 714.58 | −26.7% | 463.50 | +13.1% |
| Other income | 2.30 | 11.82 | −80.5% | 4.80 | −52.1% |
| Total income | 526.30 | 726.40 | −27.5% | 468.30 | +12.4% |
| Profit before tax | 112.59 | 209.88 | −46.4% | 92.10 | +22.2% |
| Net profit for the period | 82.19 | 151.95 | −45.9% | 103.20 | −20.4% |
| EPS, basic (₹) | 35.69 | 65.95 | −45.9% | 44.81 | −20.3% |
| Net margin (%) | 15.7 | 21.3 | 22.3 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 524.00 | 714.58 | −26.7% | 463.50 | +13.1% |
| Other income | 2.30 | 11.82 | −80.5% | 4.80 | −52.1% |
| Total income | 526.30 | 726.40 | −27.5% | 468.30 | +12.4% |
| Profit before tax | 112.59 | 210.07 | −46.4% | 92.10 | +22.2% |
| Net profit for the period | 82.19 | 152.14 | −46.0% | 103.40 | −20.5% |
| EPS, basic (₹) | 35.69 | 66.08 | −46.0% | 44.90 | −20.5% |
| Net margin (%) | 15.7 | 21.3 | 22.3 |
Consolidated
- Filed with BSE
- 07 Nov 2024, 18:23 IST
- Board meeting
- 07 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2024, 18:23 IST
- Board meeting
- 07 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE